E7386 clinical trials
E7386 is named as an intervention in 3 current clinical trials in our USA, Japan, UK, China, France, Spain, Italy, Denmark, Canada, South Korea and Taiwan registers. None are recruiting at the moment. The most common phase is Phase 1. The sponsor with the most trials is Eisai Inc (2). The most-studied condition is Advanced Neoplasms.
How E7386 works
All drug targets →- Colorectal cancerPhase 1/2
- Endometrial carcinomaPhase 1/2
- Hepatocellular carcinomaPhase 1/2
- MelanomaPhase 1/2
- NeoplasmPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297491, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for E7386
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of E7386
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797 · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
|
Phase 1/2 | Active, closed | Eisai Inc | USA, China, France, Spain, Italy, Denmark, Canada, Japan, South Korea, Taiwan |
|
Study of E7386 in Participants With Selected Advanced Neoplasms
NCT03264664 · Advanced Neoplasms
|
Phase 1 | Active, closed | Eisai Inc | UK, USA |
|
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
NCT03833700 · ClinicalTrials.gov ↗ · Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
|
Phase 1 | Active, closed | Eisai Co., Ltd | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with E7386
8 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eisai Inc | 2 |
| Eisai Co., Ltd | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about E7386 trials
How many clinical trials are testing E7386?
3 current trials in our USA, Japan, UK, China, France, Spain, Italy, Denmark, Canada, South Korea and Taiwan registers name E7386 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are E7386 trials recruiting patients?
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors E7386 clinical trials?
Eisai Inc (2) and Eisai Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how E7386 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how E7386 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists E7386 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.